Novartis News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

08.10.16	Press Release: Novartis' Tafinlar(R) (dabrafenib) -2- (Dow Jones)
08.10.16	Press Release: Novartis' Tafinlar(R) (dabrafenib) + Mekinist(R) (trametinib) demonstrate superior overall survival benefit in advanced melanoma patients at t... (Dow Jones)
08.10.16	Press Release: Novartis breakthrough therapy -2- (Dow Jones)
08.10.16	Press Release: Novartis breakthrough therapy LEE011 plus letrozole demonstrates superior progression-free survival as first-line treatment for HR+/HER2- adva... (Dow Jones)
07.10.16	Coherus' Neulasta Biosimilar At FDA Altar, CytoDyn On Fast Track, VIVE Abuzz (RTTNews)
04.10.16	MÄRKTE EUROPA/Wenig veränderte Eröffnung - Dt. Bank weiter im Fokus (Dow Jones)
03.10.16	Press Release: Novartis reports over half of -2- (Dow Jones)
03.10.16	Press Release: Novartis reports over half of psoriasis patients do not reach the achievable treatment goal of clear skin in largest global survey (Dow Jones)
01.10.16	Novartis' Cosentyx Shows High, Long-lasting Skin Clearance In Plaque Psoriasis (RTTNews)
01.10.16	Press Release: Novartis late-breaking data show -2- (Dow Jones)
01.10.16	Press Release: Novartis late-breaking data show Cosentyx delivers high and long-lasting skin clearance over 4 years for psoriasis patients (Dow Jones)
29.09.16	Press Release: Novartis announces Phase III study shows AMG 334 significantly reduces monthly migraine days in people with episodic migraine (Dow Jones)
28.09.16	Press Release: Novartis announces Phase III study -2- (Dow Jones)
28.09.16	Press Release: Novartis announces Phase III study shows AMG 334 significantly reduces monthly migraine days in people with episodic migraine (Dow Jones)
28.09.16	Press Release: Sandoz invites young entrepreneurs to enter Sandoz HACk, a global competition to help solve healthcare access challenges (Dow Jones)
26.09.16	FDA Approves AMGN's 1st Biosimilar, MRNS On Track, All Ears For DRRX, PTIE (RTTNews)
23.09.16	Press Release: Novartis receives three new FDA -2- (Dow Jones)
23.09.16	Press Release: Novartis receives three new FDA approvals for the expanded use of Ilaris treating rare Periodic Fever Syndrome conditions (Dow Jones)
23.09.16	Press Release: Novartis announces positive -2- (Dow Jones)
23.09.16	Press Release: Novartis announces positive top-line results from ASCEND-4, a Phase III trial of Zykadia(R) in untreated adult ALK+ NSCLC patients (Dow Jones)
23.09.16	Novartis: Zykadia Phase III Trial Meets Primary Endpoint - Quick Facts (RTTNews)
22.09.16	Novartis' Antimalarial Compound Shows Activity Against Vivax, Falciparum Malaria (RTTNews)
22.09.16	Press Release: Novel Novartis malaria compound shows potential to be effective against infections resistant to all currently available antimalarial drugs (Dow Jones)
21.09.16	Press Release: Novel Novartis malaria compound shows potential to be effective against infections resistant to all currently available antimalarial drugs (Dow Jones)
19.09.16	Press Release: Important new analysis shows that -2- (Dow Jones)
19.09.16	Press Release: Important new analysis shows that Novartis' Entresto(R) is associated with higher relative health-related quality of life scores among HFrEF p... (Dow Jones)
17.09.16	Novartis Reports Positive Results From Phase III EXPAND Study (RTTNews)
17.09.16	Press Release: Novartis BAF312 reduces the risk -2- (Dow Jones)
17.09.16	Press Release: Novartis BAF312 reduces the risk of disability progression in pivotal phase III study in secondary progressive MS patients (Dow Jones)
16.09.16	Press Release: New Novartis data presented at -2- (Dow Jones)
16.09.16	Press Release: New Novartis data presented at ECTRIMS show benefit of Gilenya(R) on patient disability progression at 10 years (Dow Jones)
16.09.16	Novartis Says AMG 334 Reduces Monthly Migraine Days In Chronic Migraine (RTTNews)
15.09.16	Press Release: Novartis presents new positive -2- (Dow Jones)
15.09.16	Press Release: Novartis presents new positive data at EHMTIC showing AMG 334 significantly reduces monthly migraine days in chronic migraine (Dow Jones)
15.09.16	Press Release: Novartis Foundation showcases progress in leprosy elimination programs at 19th International Leprosy Congress (Dow Jones)
09.09.16	Press Release: New Novartis point of care -2- (Dow Jones)
09.09.16	Press Release: New Novartis point of care Niji(TM) System may provide earlier diagnosis of severe allergic asthma and faster treatment decisions (Dow Jones)
08.09.16	Press Release: Novartis: Alcon launches the -2- (Dow Jones)
08.09.16	Press Release: Novartis: Alcon launches the NGENUITY(R) 3D Visualization System designed to further enhance retinal surgeon experience (Dow Jones)
08.09.16	Novartis: Alcon, TrueVision 3D Launch NGENUITY 3D Visualization System (RTTNews)
05.09.16	Vectura: Study Confirms Ultibro Breezhaler More Effective Than Seretide (RTTNews)
03.09.16	Press Release: Novartis' Ultibro(R) Breezhaler(R) -2- (Dow Jones)
03.09.16	Press Release: Novartis' Ultibro(R) Breezhaler(R) consistently more effective than Seretide(R)* in reducing COPD flare-ups across different patient groups (Dow Jones)
31.08.16	MÄRKTE EUROPA/Leichter - Konsolidierungsfantasie treibt Banken (Dow Jones)
31.08.16	MÄRKTE EUROPA/Bankenaktien ziehen Europa ins Plus (Dow Jones)
31.08.16	MÄRKTE EUROPA/Bankenaktien erneut Tagessieger (Dow Jones)
31.08.16	MÄRKTE EUROPA/Risikobereitschaft der Investoren steigt (Dow Jones)
31.08.16	CEMP To Face FDA Panel, RIGL On A High, FDA Nod For Erelzi, KPTI Awaits STORM (RTTNews)
31.08.16	Press Release: AirFluSal(R) Forspiro(R) showed -2- (Dow Jones)
31.08.16	Press Release: AirFluSal(R) Forspiro(R) showed superiority at 12 months over Seretide(R) Diskus(R)[1] in persistence to treatment (Dow Jones)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	71.14	1.54 %	K V
UBS Group	28.08	1.48 %	K V
Swiss Re	130.05	1.05 %	K V
Part Grp Hldg	1’266.00	0.96 %	K V
ABB	49.48	0.94 %	K V
Geberit	525.20	0.27 %	K V
Alcon	78.04	0.05 %	K V
Givaudan	3’868.00	-0.31 %	K V
CieFinRichemont	121.20	-0.57 %	K V
Sonova Hldg	301.00	-0.99 %	K V

mehr

12.07.24		Novartis- und MorphoSys-Aktien gewinnen: Novartis kurbelt Squeeze-Out bei MorphoSys an
12.03.24		MorphoSys- und Novartis-Aktien uneinig: Bundeskartellamt erlaubt MorphoSys-Übernahme durch Novartis
31.01.24		Novartis-Aktie schwach: Novartis profitiert von Sandoz-Abspaltung - Gewinnsprung
12.06.23		Novartis-Aktie im Plus: Novartis legt für Chinook Milliardensumme auf den Tisch
25.04.23		Novartis-Aktie im Plus: Novartis hebt nach gutem Jahresbeginn die Umsatzprognose an
07.12.22		MorphoSys-Aktie und Novartis-Aktie gefragt: Krebsprogramm gegen Zahlung an Novartis auslizenziert
19.07.22		Novartis-Aktie höher: Novartis bei nahezu stabilen Umsätzen mit Gewinnrückgang - Umbau soll 1,5 Milliarden US-Dollar Kosten sparen
06.05.22		Novartis-Aktie im Minus: Produktion von Krebsmitteln in Italien und USA ausgesetzt

12.07.24

Novartis- und MorphoSys-Aktien gewinnen: Novartis kurbelt Squeeze-Out bei MorphoSys an

12.03.24

MorphoSys- und Novartis-Aktien uneinig: Bundeskartellamt erlaubt MorphoSys-Übernahme durch Novartis

31.01.24

Novartis-Aktie schwach: Novartis profitiert von Sandoz-Abspaltung - Gewinnsprung

12.06.23

Novartis-Aktie im Plus: Novartis legt für Chinook Milliardensumme auf den Tisch

25.04.23

Novartis-Aktie im Plus: Novartis hebt nach gutem Jahresbeginn die Umsatzprognose an

07.12.22

MorphoSys-Aktie und Novartis-Aktie gefragt: Krebsprogramm gegen Zahlung an Novartis auslizenziert